Zevra Therapeutics shares accelerated nearly 14.5% in afternoon trading following a substantial reassessment by Cantor Fitzgerald, which raised its price target on the rare disease biotech from $24.00 to $34.00 and kept an Overweight rating in place. The new target represents a 41.7% increase in the firm’s valuation benchmark and was cited by market participants as the primary catalyst for the session’s sharp uptick.
At the time of the move, ZVRA stock was trading at $12.08 and reached an intraday high of $12.35. The surge marked the company’s most pronounced single-session gain in recent months and pushed the share price closer to its 52-week high of $13.16.
Analyst activity landed against a backdrop of already positive sentiment on Wall Street. Zevra entered the day supported by nine buy ratings and no hold or sell recommendations, reflecting a uniformly bullish consensus among covering analysts. Market observers noted that Cantor Fitzgerald’s upgrade set a new high-water mark among analyst price targets for the company.
Underlying the optimism are Zevra’s first-quarter 2026 financial results, which exceeded expectations. The company reported earnings of $0.18 per share, compared with a consensus of $0.06, and recorded revenue of $36.22 million versus roughly $31.96 million expected by analysts. These results were cited alongside the analyst action as reinforcing investor confidence in the firm’s near-term fundamentals.
Adding to the positive technical and fundamental signals, Zevra announced an Orange Book listing for a U.S. patent tied to MIPLYFFA, its treatment for Niemann-Pick disease type C. The entry was described as strengthening the drug’s exclusivity profile, a point that investors appeared to reward in the trading session.
The broader equity market provided a modestly favorable setting for the jump. The NASDAQ Composite advanced 0.9% on the session, which can help growth-oriented biotechnology stocks, while the S&P 500 rose 0.3%. There were no major Federal Reserve announcements or market-moving macroeconomic data reported that materially shifted the session’s tone for healthcare equities.
Market participants pointed to a confluence of factors in explaining the move: the high-profile analyst upgrade, solid reported results for Q1 2026, a debt-free balance sheet cited by the company, and the freshly noted intellectual property protection for MIPLYFFA. Together, those elements combined to generate a notable spike in ZVRA shares during the trading day.
Context note: The stock move was driven primarily by the Cantor Fitzgerald price-target increase and company disclosures reported during the session.